UNIGE document Scientific Article
previous document  unige:132612  next document
add to browser collection

Antibodies against HPV16E6 oncoprotein in the Swiss HIV cohort study: Kinetics and anal cancer risk prediction

Combes, Jean-Damien
Clifford, Gary M
Günthard, Huldrych F
Hauser, Christoph
Darling, Katharine E A
Valladares, Pablo
Battegay, Manuel
Waldeck, Frederike
show hidden authors show all authors [1 - 14]
Published in International Journal of Cancer. 2019
Abstract Our aim was to describe HPV16E6 antibody kinetics prior to anal cancer in people living with HIV/AIDS (PLWHA) and evaluate the possible contribution of HPV16E6 serology to anal cancer risk prediction. For 91 persons diagnosed with anal cancer in the Swiss HIV Cohort Study (1989-2017), serial serum/plasma samples were tested for HPV16E6 antibodies using multiplex serology, supplemented with samples from 1,356 participants without anal cancer. Anal cancer incidence was estimated for PLWHA from 40 years-old in the cART era, stratified by HPV16E6 serostatus. HPV16E6 seroprevalence was 23.3% in samples <2 years prior to anal cancer diagnosis and decreased with increasing time prior to cancer: 16.7% at 2-4 years, 4.4% at 5-9, and 7.0% at ≥10 years. Of 25 individuals with anal cancer who were HPV16E6-seropositive at any time during follow-up, the majority (n = 18) remained seropositive in all samples after seroconversion, whereas for seven cases, seropositivity was transitory. Among individuals with anal cancer, HPV16E6 seroprevalence was marginally higher in women vs. men who have sex with men (adjusted OR = 4.3, 95% CI: 1.1, 17.2) and in older participants (adjusted OR = 6.2, 95% CI: 1.1, 34.8 for cases diagnosed at ≥55 vs. <45 years). Anal cancer incidence was 402/100,000 person-years in HPV16E6-positive vs. 82/100,000 in HPV16E6-negative PLWHA (incidence rate ratio = 4.9, 95% CI: 1.3, 13.1). In conclusion, HPV16E6 serology, despite its low sensitivity, allows characterization of a group of individuals with very high anal cancer incidence and may have a place in secondary prevention in groups at high risk for anal cancer such as PLWHA.
Keywords HIVHPVAnal cancerKineticsSerology
PMID: 31722114
Full text
Article (Accepted version) (523 Kb) - public document Free access
Article (Published version) (652 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research group Maladies infectieuses et modèles mathématiques (988)
Swiss National Science Foundation: 177499
(ISO format)
COMBES, Jean-Damien et al. Antibodies against HPV16E6 oncoprotein in the Swiss HIV cohort study: Kinetics and anal cancer risk prediction. In: International Journal of Cancer, 2019. doi: 10.1002/ijc.32784 https://archive-ouverte.unige.ch/unige:132612

149 hits



Deposited on : 2020-03-19

Export document
Format :
Citation style :